ClinicalTrials.gg
CompletedNCT02965040Updated Feb 12, 2020

A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function

A Phase 1 interventional study of Roxadustat in Normal Renal Function and Impaired Renal Function, sponsored by Astellas Pharma Europe B.V.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-12.

Sponsored by Astellas Pharma Europe B.V. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Renal Insufficiency by Astellas Pharma Inc — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · Astellas Pharma Inc.

Enrollment
9th of 16
34 · median 35
Started
2016
the only one that year
Phase 1
9 of 17
none open now
Registered
14th of 17
by date

Among the 17 studies in Renal Insufficiency by Astellas Pharma Inc, this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2016, is one of 9 in phase 1, and was the 14th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 17 studies in Renal Insufficiency by Astellas Pharma Inc is open now. The open studies under Renal Insufficiency, anywhere →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Renal Insufficiency by Astellas Pharma Inc as a file.
02

Study summary

For subjects with normal renal function or severely impaired renal function, this study will evaluate the pharmacokinetics of roxadustat and its main metabolites in plasma and urine.

For subjects with end stage renal disease (ESRD) on continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD), this study will evaluate the pharmacokinetics of roxadustat and its main metabolites in plasma, urine and dialysate.

For subjects with ESRD on hemodialysis (HD) or hemodiafiltration (HDF), this study will evaluate the pharmacokinetics of roxadustat and its main metabolites in plasma, urine and dialysate and also the effect of dialysis on the pharmacokinetics of roxadustat and its main metabolites.

Read the detailed description

This is a phase 1, open-label study in two sites. There will be four different renal function groups.

For all subjects:

Subjects will be allocated to the normal and severely impaired renal function groups based on estimated glomerular filtration rate (eGFR), calculated with the abbreviated modification of diet in renal disease (MDRD) equation. The eGFR will be based on the serum creatinine concentration and is assessed at screening and at day -2. The eGFR obtained at screening will determine the allocation.

Subjects will be allocated to the ESRD groups based on their dialysis requirements.

Subjects with normal and severely impaired renal function, and subjects with ESRD on CAPD or APD:

Screening will take place from day -30 to day -3 and the subjects will be admitted to the clinical unit on day -2. The treatment period lasts 8 days, during which the subjects will receive a single oral dose of roxadustat in the morning of day 1 Subjects will complete the treatment period on day 6, provided that all required assessments have been performed and there are no medical reasons for a prolonged follow-up. The study will be completed with an end-of-study visit (ESV), which will take place between 5 and 9 days after the last treatment period-defined assessment (or after early withdrawal).

Subjects with ESRD on HD or HDF:

Screening will take place from day -30 to day -3 and subjects will complete 2 treatment periods of 8 days (period 1) and 7 days (period 2) in order to evaluate the pharmacokinetics of roxadustat with a single oral dose of roxadustat on day 1 of both periods after and before dialysis.

Subjects will complete the treatment period 1 on day 6 followed by a wash-out period which is minimally 1 week and maximally 3 weeks. Subjects will complete period 2 on day 6, provided that all required assessments have been performed and there are no medical reasons for a prolonged follow-up. The study will be completed with an end-of-study visit (ESV), which will take place between 5 and 9 days after the last treatment period-defined assessment (or after early withdrawal).

All subjects:

Safety assessments will be performed throughout the study. An optional biobanking sample may be taken for potential exploratory, retrospective, gene polymorphism analysis. Roxadustat plasma, urine, and dialysate samples will be stored for potential exploratory metabolic profiling or exploratory biomarker analysis after the study.

03

Conditions studied

  • Normal Renal Function
  • Impaired Renal Function

Browse trials for

Keywords

  • ASP1517
  • Normal renal function
  • Dialysis
  • Roxadustat
  • Metabolites
  • Pharmacokinetics
  • Impaired renal function
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Inclusion criteria for all subjects:

  • Subject has a body weight of 45 to 160 kg, inclusive.
  • For subjects with ESRD on CAPD or APD body weight should be recorded as the measured body weight minus abdominal dialysis fluid based on the last filling. For subjects with ESRD on HD or HDF the post-dialysis body weight will be recorded.

Specific inclusion criteria for subjects with normal renal function:

  • Subject is a healthy male or female subject aged 40 to 75 years, inclusive.
  • Subject must have a pre-dose value based on the abbreviated MDRD method of greater than or equal to 90 mL/min/1.73 m\^2.

Specific inclusion criteria for subjects with severely impaired renal function:

  • Subject is a male or female subject aged 18 to 75 years, inclusive.
  • Subject must have a pre-dose eGFR value based on the abbreviated MDRD method [screening] of \<30 mL/min/1.73 m\^2 and not be on dialysis.

Specific inclusion criteria for subjects with ESRD on CAPD or APD:

  • Subject is a male or female subject aged 18 to 75 years, inclusive.
  • Subject is on CAPD or APD treatment with the same mode of dialysis for at least 4 months prior to admission to the clinical unit.

Specific inclusion criteria for subjects with ESRD on HD or HDF:

  • Subject is a male or female subject aged 18 to 75 years, inclusive.
  • Subject is on HD or HDF treatment with the same mode of dialysis for at least 4 months prior to admission to the clinical unit and should have dialysis sessions three times weekly.

Specific inclusion criteria for subjects with impaired renal function including severly impaired renal function and ESRD:

  • If a subject is being treated with short-acting ESAs, the subject agrees to discontinue treatment for at least 14 days prior to admission.

Exclusion Criteria:

Exclusion criteria for all subjects:

  • Subject has a known or suspected to Roxadustat or any components (e.g., lactose) of the formulations used.
  • Subject has any history of allergic conditions (including drug allergies or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (noncutaneous) infection within 1 week prior to admission to the clinical unit.
  • Subject has any clinically significant abnormality following the investigator's review of the physical examination, (ECG), and clinical study protocol-defined clinical laboratory tests at screening or day -2.
  • Subject has a history of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the clinical unit.
  • Subject has a history of drinking more than 21 units (male subjects) or more than 14 units (female subjects) of alcohol per week (1 unit = 10 g pure alcohol = 250 mL of beer [5%] or 35 mL of spirits [35%] or 100 mL of wine [12%]) within 3 months prior to admission to the clinical unit.
  • Subject uses moderate or strong inducers of metabolism (e.g., barbiturates, rifampin) regularly in the 1 month prior to admission to the clinical unit.
  • Subject must not consume grapefruit (or any grapefruit-containing products, including juice) or Seville oranges (or any Seville orange-containing products, including juice) within 7 days prior to admission to the clinical unit.
  • Subject uses any drugs of abuse within 3 months prior to admission to the clinical unit.
  • Subject has a positive serology test for surface antigen (HBsAg), anti-hepatitis A virus (immunoglobulin M [IgM]), anti- virus, hepatitis B core antibody or anti- (HIV) type 1 or 2 [screening].
  • Subject participated in any clinical study or has been treated with any drugs within 28 days (or 5 half-lives whichever is longer), prior to screening.
  • Subject has any condition which makes the subject unsuitable for clinical study participation.
  • Subject is a vulnerable subject (e.g., subject kept in detention).

Specific exclusion criteria for subjects with normal renal function:

  • Subjects aged greater than or equal to 40 and \< 65:

    • Subject has a mean pulse \< 45 or >90 bpm; mean systolic blood pressure \<90 mmHg and >140 mmHg; mean diastolic blood pressure \<50 mmHg and >90 mmHg at day -2. Vital signs measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse will be measured automatically. If the mean pulse, systolic blood pressure or diastolic blood pressure exceeds the limits above, 1 additional triplicate can be taken [day -2].
  • Subjects aged greater than or equal to 65 and less than or equal to 75:

    • Subject has a mean pulse \<45 or >90 bpm; mean systolic blood pressure \<90 mmHg and >160 mmHg; mean diastolic blood pressure \<50 mmHg and >100 mmHg at day -2. Vital signs measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse will be measured automatically. If the mean pulse, systolic blood pressure or diastolic blood pressure exceeds the limits above, 1 additional triplicate can be taken [day -2].
  • Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, psychiatric, dermatologic, renal and/or other major disease or .
  • Subjects aged greater than or equal to 40 and \<65:

    • Subject has a mean interval using Fridericia's formula (QTcF) >430 ms (for males) and >450 ms (for females) at day 2. If the mean QTcF exceeds the limits above, 1 additional triplicate Electrocardiogram (ECG) can be taken (day -2).
  • Subjects aged greater than or equal to 65 and less than or equal to 75:

    • Subject has a mean QTcF >450 ms (for males) and >470 ms (for females) at day 2. If the mean QTcF exceeds the limits above, 1 additional triplicate ECG can be taken (day -2).
  • Subject has any of the liver chemistry tests ( [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP], gamma-glutamyl transferase [GGT] and total [TBL]) above 1.5 times the (ULN) at day -2. In such a case, the assessment may be repeated once [day -2].
  • Subject uses any prescribed or non-prescribed drugs (including vitamins, calcium, magnesium and iron supplements, natural- and herbal- remedies, e.g., St. John's Wort) within 2 weeks (or 5 half-lives, whichever is longer) prior to admission to the clinical unit, except for occasional use of paracetamol (up to 2 g per day) and oral or hormone replacement therapy.

Specific exclusion criteria for subjects with impaired renal function (including severely impaired renal function and ESRD):

  • Subject has a mean pulse \<45 or >90 bpm; mean systolic blood pressure \<90 mmHg and >160 mmHg; mean diastolic blood pressure \<50 mmHg and >100 mmHg at day -2. Vital signs measurements, taken in triplicate after the subject has been resting in supine position for 5 minutes; pulse will be measured automatically. If the mean pulse, systolic blood pressure or diastolic blood pressure exceeds the limits above, 1 additional triplicate can be taken [day -2].
  • Subject has a history of any clinically significant illness (other than renal disease and conditions related to the renal disease, such as stable diabetes and stable hypertension), medical condition, or laboratory abnormality within 3 months prior to screening that would preclude participation in the clinical study.
  • Subject has used drugs or drugs used to treat malignancies (including at doses >10 mg prednisolone per day or equivalent) within 3 months prior to admission to the clinical unit.
  • Subject is anticipated to undergo surgery that is expected to lead to significant blood loss during the clinical study period or anticipated coronary revascularization.
  • Subject has an anticipated use of the following prohibited medication during the treatment and/or follow-up of the study:

    • Oral multivalent cation-containing drugs and mineral supplements (e.g., iron, calcium, magnesium, aluminium), anion-exchange resins (e.g., colestyramine), sucralfate or magnesium- or aluminium-containing antacids, phosphate binders, and iron-chelating agents are not allowed from 24 hours before until 48 hours after dosing.
    • Short-acting intravenous (IV) or subcutaneous (SC) Erythropoiesis stimulating agents (ESA) are not allowed within 2 weeks prior to admission to the clinical unit until the ESV.
    • Dapsone in any dose amount or anticipated chronic use of paracetamol >2 g/day or nonsteroidal anti-inflammatory drugs (NSAIDs), except for low dose aspirin/acetylsalicylic acid, is not allowed from admission to the clinical unit until the ESV.
  • Subject has not been on a stable dose of concomitant medication to treat concurrent chronic conditions for at least 2 weeks (or 5 half-lives of the drug, whichever is longer) prior to admission to the clinical unit (minor dose changes are allowed in agreement with Sponsor). Doses of statins should not exceed the capped maximum daily doses at admission to the clinical unit. Rosuvastatin use is not allowed.
  • Subject who requires, or is likely to require, any new concomitant medication from the time of screening until the ESV.
  • Subject has used any non-essential prescribed and non-prescribed drugs (including vitamins, natural- and herbal-remedies (e.g., St. John's Wort) within 2 weeks (or 5 half-lives, whichever is longer) prior to admission to the clinical unit.
  • Subject has a mean QTcF >450 ms (for males) and >470 ms (for females) at day 2. If the mean QTcF exceeds the limits above, 1 additional triplicate ECG can be taken (day -2).
  • Subject who has renal disease secondary to malignancy.
  • Subject who has a fluctuating or rapidly deteriorating renal function within 4 weeks prior to admission to the clinical unit, as indicated by strongly varying or worsening of clinical and/or laboratory signs of renal impairment within the screening period.
  • Subject with serum uric acid >2 x the ULN. In such a case the assessment may be repeated once [day -2].
  • Subject with any of the liver chemistry tests (AST, ALT and TBL) out of range as indicated below. In such a case the assessment may be repeated once [day -2].

    • ALT or AST >3 x ULN
    • TBL >1.5 x ULN
  • Subject has had any prior organ transplant (that has not been explanted) or subject is scheduled for organ transplantation.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Roxadustat: subjects with normal renal function

    Normal renal function: eGFR is equal to or greater than 90 mL/min/1.73 m\^2. Single dose of roxadustat

    Drug: Roxadustat

  • Experimental
    Roxadustat: subjects with severely impaired renal function

    Severely impaired renal function: eGFR is less than 30 mL/min/1.73 m\^2. Single dose of roxadustat

    Drug: Roxadustat

  • Experimental
    Roxadustat: subjects with ESRD on CAPD or APD

    ESRD subjects on CAPD or APD need to be on the same mode of dialysis for at least 4 months. Single dose of roxadustat

    Drug: Roxadustat

  • Experimental
    Roxadustat: subjects with ESRD on HD or HDF

    ESRD subjects on HD or HDF need to be on the same mode of dialysis for at least 4 months and should have dialysis sessions three times weekly. Single dose of roxadustat, in both treatment periods

    Drug: Roxadustat

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of Roxadustat in plasma: Cmax

    Cmax: Maximum concentration

    Time frame: Up to day 6

  2. Pharmacokinetics of Roxadustat in plasma: Cmax,u

    Cmax,u: Maximum concentration of unbound compound

    Time frame: Up to day 6

  3. Pharmacokinetics of Roxadustat in plasma: AUCinf

    AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity

    Time frame: Up to day 6

  4. Pharmacokinetics of Roxadustat in plasma: AUCinf,u

    AUCinf,u: Area under the concentration-time curve from the time of dosing extrapolated to time infinity for unbound concentration

    Time frame: Up to day 6

  5. Pharmacokinetics of Roxadustat in plasma: AUClast

    AUClast: Area under the concentration-time curve from the time of dosing to the last measurable concentration (Clast)

    Time frame: Up to day 6

  6. Pharmacokinetics of Roxadustat in plasma: AUClast,u

    AUClast,u: Area under the concentration-time curve from the time of dosing to the last measurable concentration (Clast) for unbound concentration

    Time frame: Up to day 6

  7. Pharmacokinetics of Roxadustat in plasma: CL/F

    CL/F: Apparent total systemic clearance after single or multiple extravascular dosing

    Time frame: Up to day 6

  8. Pharmacokinetics of Roxadustat in plasma: CLu/F

    CLu/F: Apparent total systemic clearance of unbound compound after extravascular dosing

    Time frame: Up to day 6

  9. Pharmacokinetics of Roxadustat in plasma: fu

    fu: Fraction of parent or metabolite available systemically unbound (= free fraction)

    Time frame: Up to day 6

  10. Pharmacokinetics of Roxadustat in plasma: tmax

    tmax: Time of the maximum concentration

    Time frame: Up to day 6

  11. Pharmacokinetics of Roxadustat in plasma t1/2

    t1/2: Terminal elimination half-life

    Time frame: Up to day 6

  12. Pharmacokinetics of Roxadustat in plasma: Vz/F

    Vz/F: Apparent volume of distribution during the terminal elimination phase after single extravascular dosing

    Time frame: Up to day 6

  13. Pharmacokinetics of Roxadustat in plasma: Vz,u/F

    Vz,u/F: Apparent volume of distribution during the terminal elimination phase of unbound compound after extravascular dosing

    Time frame: Up to day 6

  14. Pharmacokinetics of O-glucuronide-Roxadustat in plasma: Cmax

    Time frame: Up to day 6

  15. Pharmacokinetics of O-glucuronide-Roxadustat in plasma: AUCinf

    Time frame: Up to day 6

  16. Pharmacokinetics of O-glucuronide-Roxadustat in plasma: AUClast

    Time frame: Up to day 6

  17. Pharmacokinetics of O-glucuronide-Roxadustat in plasma: tlag

    tlag: Time prior to the time corresponding to the first measurable (non-zero) concentration

    Time frame: Up to day 6

  18. Pharmacokinetics of O-glucuronide-Roxadustat in plasma: tmax

    Time frame: Up to day 6

  19. Pharmacokinetics of O-glucuronide-Roxadustat in plasma: t1/2

    Time frame: Up to day 6

  20. Pharmacokinetics of O-glucuronide-Roxadustat in plasma: MPR

    MPR: Metabolite to parent ratio of AUC using AUC (corrected) for the metabolite (corrected by molecular weight ratio of parent to metabolite)

    Time frame: Up to day 6

  21. Pharmacokinetics of O-glucoside -Roxadustat in plasma: Cmax

    Time frame: Up to day 6

  22. Pharmacokinetics of O-glucoside-Roxadustat in plasma: AUCinf

    Time frame: Up to day 6

  23. Pharmacokinetics of O-glucoside-Roxadustat in plasma: AUClast

    Time frame: Up to day 6

  24. Pharmacokinetics of O-glucoside-Roxadustat in plasma: tlag

    tlag: Time prior to the time corresponding to the first measurable (non-zero) concentration

    Time frame: Up to day 6

  25. Pharmacokinetics of O-glucoside-Roxadustat in plasma: tmax

    Time frame: Up to day 6

  26. Pharmacokinetics of O-glucoside-Roxadustat in plasma: t1/2

    Time frame: Up to day 6

  27. Pharmacokinetics of O-glucoside-Roxadustat in plasma: MPR

    MPR: Metabolite to parent ratio of AUC using AUC(corrected) for the metabolite (corrected by molecular weight ratio of parent to metabolite)

    Time frame: Up to day 6

  28. Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: Cmax

    Time frame: Up to day 6

  29. Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: AUCinf

    Time frame: Up to day 6

  30. Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: AUClast

    Time frame: Up to day 6

  31. Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: tlag

    tlag: Time prior to the time corresponding to the first measurable (non-zero) concentration

    Time frame: Up to day 6

  32. Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: tmax

    Time frame: Up to day 6

  33. Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: t1/2

    Time frame: Up to day 6

  34. Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: MPR

    Time frame: Up to day 6

  35. Pharmacokinetics of Roxadustat in urine: CLR

    CLR: Renal clearance

    Time frame: Up to day 4

  36. Pharmacokinetics of Roxadustat in urine: CLR,u

    CLR,u: Renal clearance of unbound drug

    Time frame: Up to day 4

  37. Pharmacokinetics of Roxadustat in urine: Aeinf

    Aeinf: Cumulative amount of compound excreted into urine from time of dosing extrapolated to time infinity

    Time frame: Up to day 4

  38. Pharmacokinetics of Roxadustat in urine: Aeinf%

    Aeinf%: Percent of drug dose excreted into urine (Aeinf) from time of dosing extrapolated to time infinity

    Time frame: Up to day 4

  39. Pharmacokinetics of Roxadustat in urine: Aelast

    Aelast: Cumulative amount of drug excreted into urine from time of dosing up to the collection time of the last measurable concentration

    Time frame: Up to day 4

  40. Pharmacokinetics of Roxadustat in urine: Aelast%

    Aelast%: Percent of drug dose excreted into urine (Aelast) from time of dosing up to the collection time of the last measurable concentration

    Time frame: Up to day 4

  41. Pharmacokinetics of O-glucuronide-Roxadustat in urine: CLR

    Time frame: Up to day 4

  42. Pharmacokinetics of O-glucuronide-Roxadustat in urine: Aeinf

    Time frame: Up to day 4

  43. Pharmacokinetics of O-glucuronide-Roxadustat in urine: Aelast

    Time frame: Up to day 4

  44. Pharmacokinetics of O-glucuronide-Roxadustat in urine: MPR based on Aeinf

    Time frame: Up to day 4

  45. Pharmacokinetics of O-glucoside-Roxadustat in urine: CLR

    Time frame: Up to day 4

  46. Pharmacokinetics of O-glucoside-Roxadustat in urine: Aeinf

    Time frame: Up to day 4

  47. Pharmacokinetics of O-glucoside-Roxadustat in urine: Aelast

    Time frame: Up to day 4

  48. Pharmacokinetics of O-glucoside-Roxadustat in urine: MPR based on Aeinf

    Time frame: Up to day 4

  49. Pharmacokinetics of sulfate of hydroxy-Roxadustat in urine: CLR

    Time frame: Up to day 4

  50. Pharmacokinetics of sulfate of hydroxy-Roxadustat in urine: Aeinf

    Time frame: Up to day 4

  51. Pharmacokinetics of sulfate of hydroxy-Roxadustat in urine: Aelast

    Time frame: Up to day 4

  52. Pharmacokinetics of sulfate of hydroxy-Roxadustat in urine: MPR based on Aeinf

    Time frame: Up to day 4

  53. Pharmacokinetics of Roxadustat and its main metabolites in dialysate fluid: CLD

    CLD: dialysis clearance. For ESRD subjects on CAPD or APD and for ESRD subjects on HD or HDF (treatment period 2 only)

    Time frame: Up to day 2

  54. Pharmacokinetics of Roxadustat in dialysate fluid: fD

    fD: fraction of dose cleared by dialysis. For ESRD subjects on CAPD or APD and for ESRD subjects on HD or HDF (treatment period 2 only)

    Time frame: Up to day 2

  55. Pharmacokinetics of O-glucuronide-Roxadustat in urine: Aeinf%

    Time frame: Up to day 4

  56. Pharmacokinetics of O-glucoside-Roxadustat in urine: Aeinf%

    Time frame: Up to day 4

  57. Pharmacokinetics of sulfate of hydroxy-Roxadustat in urine: Aeinf%

    Time frame: Up to day 4

  58. Pharmacokinetics of Roxadustat in plasma: Effective t½ 48 hours

    Effective t½ 48 hours: Effective half-life based on a dosing interval of 48 hours

    Time frame: Up to day 6

  59. Pharmacokinetics of Roxadustat in plasma: Effective t½ 56 hours

    Effective t½ 56 hours: Effective half-life based on a dosing interval of 56 hours

    Time frame: Up to day 6

  60. Pharmacokinetics of O-glucuronide-Roxadustat in plasma: TER

    TER: Total exposure ratio

    Time frame: Up to day 6

  61. Pharmacokinetics of O-glucoside-Roxadustat in plasma: TER

    Time frame: Up to day 6

  62. Pharmacokinetics of sulfate of hydroxy-Roxadustat in plasma: TER

    Time frame: Up to day 6

Secondary outcomes

  1. Pharmacodynamics of Roxadustat assessed by measuring erythropoietin (EPO): Emax

    Emax: Maximum effect

    Time frame: Up to day 6

  2. Pharmacodynamics of Roxadustat assessed by measuring erythropoietin (EPO): Emax-baseline

    Emax-baseline: Maximum effect from baseline

    Time frame: U to day 6

  3. Pharmacodynamics of Roxadustat assessed by measuring erythropoietin (EPO): AUCE,last

    AUCE,last: Area under the effect-time curve from the time of dosing to the last measurable effect

    Time frame: Up to day 6

  4. Pharmacodynamics of Roxadustat assessed by measuring erythropoietin (EPO): AUCE,last (baseline-corrected)

    AUCE,last (baseline-corrected): Area under the effect-time curve from the time of dosing to the last measurable effect baseline corrected

    Time frame: Up to day 6

  5. Pharmacodynamics of Roxadustat assessed by measuring erythropoietin (EPO): tmax, EPO

    tmax, EPO: Time to maximum EPO concentration

    Time frame: Up to day 6

  6. Safety assessed by nature, frequency, and severity of Adverse Events (AEs)

    Time frame: Up to End of Study (EOS) (Up to day 15, period 2)

  7. Number of participants with vital signs abnormalities and/or adverse events related to treatment

    Vital signs include: blood pressure (systolic and diastolic) and pulse

    Time frame: Up to EOS (Up to day 15, period 2)

  8. Safety assessed by routine 12- lead electrocardiogram (ECG)

    Routine 12-lead ECG measurements will be performed for the different renal function groups, as applicable, after the subject has been in a supine position for at least 5 minutes. All routine 12-lead ECG data will be listed by subject

    Time frame: Up to EOS (Up to day 15, period 2)

  9. Safety assessed by continuous heart rate (HR) measurement

    Holter

    Time frame: Up to day 2 (period 1)

  10. Number of participants with laboratory value abnormalities and/or adverse events related to treatment

    Safety laboratory tests include: hematology, biochemistry and urinalysis

    Time frame: Up to EOS (Up to day 15, period 2)

07

Study locations

2 sites
  • Site DE49001
    Munchen, 81241, Germany
  • Site GB44001
    Liverpool, L7 8XP, United Kingdom
08

References and documents

Publications

  • Groenendaal-van de Meent D, Kerbusch V, Kaspera R, Barroso-Fernandez B, Galletti P, Klein GK, den Adel M. Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor. Eur J Drug Metab Pharmacokinet. 2021 Jan;46(1):141-153. doi: 10.1007/s13318-020-00658-w. PubMed 33165773 ↗

Individual participant data

Plan to share: Undecided — Studies conducted with product indications or formulations that remain in development are assessed after study completion to determine if Individual Participant Data can be shared. The plan to share Individual Participant Data is based on the status of product approval or termination of the compound, in addition to other study-specific criteria described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Dec 2017, 11 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 11 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2016
First posted
Nov 16, 2016
StartActual
Dec 12, 2016
Primary completionActual
Dec 4, 2017
CompletionActual
Dec 11, 2017
Last update
Feb 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02965040
Collaborators
FibroGen
Responsible party
Sponsor
First posted
Nov 16, 2016
Start date
Dec 12, 2016
Primary completion
Dec 4, 2017
Completion
Dec 11, 2017
Last update
Feb 12, 2020

Study contacts

Medical Monitor
study chair · Astellas Pharma Europe B.V.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion